Structure Therapeutics (NASDAQ:GPCR) just reported results for the second quarter of 2024. Structure Therapeutics reported earnings per share of -18 cents. This was above the analyst estimate for ...

Yaron Werber has given his Buy rating due to a combination of factors associated with Septerna, Inc.’s strategic approach in drug development. The company is utilizing its innovative Native ...

The GPCR-targeting therapies market is experiencing dynamic growth, driven by advances in drug discovery technologies, an expanding understanding of GPCR biology, and the therapeutic relevance of ...

Image Credit: Ph-HY/Shutterstock.com Historically, GPCRs have been one of the most important targets for drug discovery. In fact, around 30 % of all currently marketed drugs target GPCRs.

GPCR Therapeutics, Inc., headquartered in Seoul, South Korea, is a clinical-stage international biopharmaceutical company with an innovative approach to developing therapeutics built on its ...

Researchers have uncovered the fundamental mechanism how such a GPCR works. Using a method similar to the earth satellite GPS, they could track the motions of a GPCR and observe it in action.